methyl isocyanate has been researched along with laromustine in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baumann, RP; Penketh, PG; Sartorelli, AC; Seow, HA; Shyam, K | 1 |
Pigneux, A | 1 |
Cincotta, DJ; Ghazvinian, R; He, Y; Ji, W; Li, Y; Min, W; Praggastis, A; Rice, KP; Yang, M; Zhou, HJ | 1 |
1 review(s) available for methyl isocyanate and laromustine
Article | Year |
---|---|
Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Humans; Hydrazines; Isocyanates; Middle Aged; Neoplasms; Prodrugs; Sulfonamides | 2009 |
2 other study(ies) available for methyl isocyanate and laromustine
Article | Year |
---|---|
The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biotransformation; Cell Line; Cells, Cultured; CHO Cells; Cricetinae; Drug Synergism; Guanine; HL-60 Cells; Humans; Hydrazines; Isocyanates; O(6)-Methylguanine-DNA Methyltransferase; Prodrugs; Sulfonamides; Transfection | 2005 |
Carbamoylating activity associated with the activation of the antitumor agent laromustine inhibits angiogenesis by inducing ASK1-dependent endothelial cell death.
Topics: Animals; Antineoplastic Agents; Biocatalysis; Carbamates; Cattle; Cell Death; Cells, Cultured; Endothelial Cells; Humans; Hydrazines; Immunoblotting; Isocyanates; MAP Kinase Kinase Kinase 5; Mitogen-Activated Protein Kinase 8; Neovascularization, Physiologic; Signal Transduction; Sulfonamides; Thioredoxin Reductase 1; Thioredoxins | 2014 |